Valuation : Amgen Inc.

Market Cap 204B 176B 166B 151B 283B 19,490B 284B 1,977B 760B 9,916B 766B 749B 31,332B P/E 2026 *
23.9x
P/E 2027 * 21.3x
Enterprise Value 245B 212B 200B 182B 341B 23,453B 342B 2,379B 915B 11,932B 922B 902B 37,704B EV / Sales 2026 *
6.3x
EV / Sales 2027 * 5.96x
Free-Float
99.77%
Yield 2026 *
2.67%
Yield 2027 * 2.82%
1 day-0.79%
1 week-13.13%
Current month-11.72%
1 month-9.36%
3 months+6.86%
6 months+1.72%
Current year+16.77%
1 week 326.25
Extreme 326.25
360.5
1 month 326.25
Extreme 326.25
383.05
Current year 271.8
Extreme 271.8
383.05
1 year 230
Extreme 230
383.05
3 years 230
Extreme 230
383.05
5 years 174.58
Extreme 174.58
383.05
10 years 120.65
Extreme 120.65
383.05
Manager TitleAgeSince
Chief Executive Officer 63 2012-04-30
Director of Finance/CFO 62 2010-05-12
Chief Tech/Sci/R&D Officer 57 2023-05-31
Director TitleAgeSince
Chairman 63 2012-12-31
Director/Board Member 65 2011-12-31
Director/Board Member 71 2011-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%-13.13% - - 204B
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average -0.73%-5.76%+22.08%+40.35% 389.42B
Weighted average by Cap. -0.52%-4.42%+30.96%+54.95%

Financials

2026 *2027 *
Net sales 38.94B 33.55B 31.77B 28.79B 54.02B 3,720B 54.29B 377B 145B 1,893B 146B 143B 5,980B 40.23B 34.66B 32.82B 29.75B 55.81B 3,844B 56.1B 390B 150B 1,955B 151B 148B 6,179B
Net income 8.69B 7.49B 7.09B 6.43B 12.06B 830B 12.12B 84.21B 32.38B 422B 32.64B 31.92B 1,335B 9.36B 8.07B 7.64B 6.92B 12.99B 894B 13.05B 90.72B 34.88B 455B 35.16B 34.39B 1,438B
Net Debt 41.49B 35.74B 33.84B 30.68B 57.55B 3,963B 57.84B 402B 155B 2,016B 156B 152B 6,371B 35.82B 30.86B 29.22B 26.48B 49.69B 3,422B 49.94B 347B 133B 1,741B 135B 132B 5,501B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
26-09-11 €327.30 -0.79% 385
26-09-10 €329.90 -2.24% 740
26-09-09 €337.45 -0.74% 603
26-09-08 €339.95 -5.41% 680
26-09-07 €359.40 -4.61% 824
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
377.35USD
Average target price
388.03USD
Spread / Average Target
+2.83%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!